No Data
PAVmed Shares Are Trading Higher After the Company Announced It and Lucid Diagnostics Submitted Complete Clinical Evidence for Its Esoguard Esophageal DNA Test.
Lucid Diagnostics And Subsidiary Of PAVmed Announced That It Has Submitted Its Complete Clinical Evidence Package For Its Esoguard Esophageal DNA Test To Molecular Diagnostics Program Seeking Medicare Coverage For Esoguard Esophageal DNA Test
PAVmed Positioned for Growth Despite Q3 Revenue Miss: Buy Rating Affirmed by Anthony Vendetti
Q3 2024 PAVmed Inc Earnings Call
PAVmed Inc. (PAVM) Q3 2024 Earnings Call Transcript Summary
10-Q: Q3 2024 Earnings Report
No Data
No Data